PHARMACEUTICAL DIRECTORY AND HANDBOOK

By CHARLES MILLER

CONTENTS 1 THE EVOLUTION OF DRUG METABOLISM RESEARCH 2 PHARMACOKINETICS OF DRUG METABOLITES 3 HEPATIC ARCHITECTURE: FUNCTIONAL AND SUBCELLULAR CORRELATES 4 THE CYTOCHROME P450 OXIDATIVE SYSTEM 6 UDP-GLUCURONOSYLTRANSFERASES 7 PHARMACOGENETICS 8 INHIBITION OF DRUG METABOLIZING ENZYMES 9 THE ONTOGENY OF DRUG METABOLIZING ENZYMES/PEDIATRIC EXCLUSIVITY 10 SITES OF EXTRA HEPATIC METABOLISM, PART I: LUNG 11 SITES OF EXTRA HEPATIC METABOLISM, PART II: GUT 12 SITES OF EXTRA HEPATIC METABOLISM, PART III: KIDNEY 13 SITES OF EXTRA HEPATIC METABOLISM, PART IV: BRAIN 14 LC-MS ANALYSIS IN DRUG METABOLISM STUDIES 15 THE PRACTICE OF NMR SPECTROSCOPY IN DRUG METABOLISM STUDIES 16 APPLICATIONS OF RECOMBINANT AND PURIFIED HUMAN DRUG-METABOLIZING ENZYMES: AN INDUSTRIAL PERSPECTIVE 17 IN VITRO METABOLISM: SUBCELLULAR FRACTIONS 18 IN VITRO METABOLISM: HEPATOCYTES 19 DRUG INTERACTION STUDIES IN THE DRUG DEVELOPMENT PROCESS: STUDIES IN VITRO 20 ENZYME INDUCTION STUDIES IN DRUG DISCOVERY & DEVELOPMENT MECHANISM BASED INHIBITION CONTENTS 22 CLINICAL DRUG METABOLISM 23 MINIMIZING METABOLIC ACTIVATION IN DRUG DISCOVERY 24 KINETIC DIFFERENCES BETWEEN GENERATED AND PREFORMED METABOLITES: A DILEMMA IN RISK ASSESSMENT 25 THE USE OF TRANSGENIC ANIMALS TO STUDY DRUG METABOLISM 26 PRECLINICAL PHARMACOKINETIC MODELS FOR DRUG DISCOVERY AND DEVELOPMENT